

# REGENERON

## Regeneron Announces Investor Conference Presentations

February 17, 2022

TARRYTOWN, N.Y., Feb. 17, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: **REGN**) will webcast management participation as follows:

- Cowen 42<sup>nd</sup> Annual Health Care Conference at 1:30 p.m. ET on Tuesday, March 8, 2022
- Oppenheimer 32<sup>nd</sup> Annual Healthcare Conference at 10:00 a.m. ET on Tuesday, March 15, 2022
- Barclays Global Healthcare Conference at 8:00 a.m. ET on Wednesday, March 16, 2022

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at <https://investor.regeneron.com/events-and-presentations>. Replays of the webcasts will be archived on the Company's website for at least 30 days.

### About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary *VelociSuite*<sup>®</sup> technologies, such as *VelocImmune*<sup>®</sup>, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit [www.regeneron.com](http://www.regeneron.com) or follow @Regeneron on Twitter.

### Contact Information:

Investor Relations

Mark Hudson

914.847.3482

[mark.hudson@regeneron.com](mailto:mark.hudson@regeneron.com)

 View original content: <https://www.prnewswire.com/news-releases/regeneron-announces-investor-conference-presentations-301484955.html>

SOURCE Regeneron Pharmaceuticals, Inc.